Demetrix has initiated its 2022 commercial manufacturing campaign to support cannabigerol (CBG) sales.
Initial global customers in the personal care and nutrition segments have agreed to purchase approximately 70% of Demetrix’s total production this year. This first commercial production run with a contract manufacturing organization is one of many the company will complete this year to support a growing external customer base.
Previously: Demetrix Signs First CMO for Cannabinoid Production
Demetrix’s commercial manufacturing campaign will support anticipated market demand and partnerships in 2022 with expanded production in 2023 and beyond.
According to the company, its CBG is identical to plant-based CBG without common impurities found with plant extraction that can create undesirable effects in consumer products. Using fermentation production, Demetrix can produce CBG at a higher purity level and with a lighter environmental footprint than agriculture.
Demetrix will officially announce this news and other developments at in-cosmetics Global this year in Paris.
“We are thrilled to announce that we are now commercially selling rare cannabinoids,” said Cynthia Bryant, chief business officer. “This achievement marks a significant step on bringing rare cannabinoids safely and legally to major, global consumer markets. Based on our research, we see strong potential for rare cannabinoids to be interesting bioactives for the consumer products industry. This is just the beginning for Demetrix. We are commercially selling CBG now and have plans to expand our capabilities and product lines over the next 18 to 24 months.”
“This successful initiation of our commercial campaign validates our achievements as a company and the benefit of taking a focused approach to scaling up production,” said Jeff Ubersax, CEO. “With the experience of our industry-leading team, we were able to do this right from the start, using resources and time wisely, and we are extremely proud of the result.”
